LX2022

About Lexeo Therapeutics

Lexeo Therapeutics is a clinical-stage biotech focused on developing AAV-based gene therapies for monogenic cardiovascular diseases and genetically defined CNS disorders. The company has built a promising pipeline, including a Phase 2 candidate for Friedreich's ataxia cardiomyopathy and a Phase 1/2 candidate for APOE4-associated Alzheimer's disease, emerging from foundational research at Weill Cornell Medicine. Its strategy centers on applying validated gene therapy constructs to high-impact, well-defined genetic drivers of disease, aiming for transformative, one-time treatments in areas of significant unmet need. Despite a challenging market valuation, Lexeo represents a focused player in the precision gene therapy space.

Therapeutic Areas